BRUSSELS (Reuters) – The European Medicines Agency will consider in the coming days whether to launch a rolling review of Merck’s experimental COVID-19 pill, its head of vaccine strategy said on Tuesday
An experimental antiviral pill developed by Merck & Co could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, interim data showed last week.
“We will be considering whether to start a rolling review for this compound in the next days. And of course, the idea is to understand if the data supports such (a) rolling review,” Marco Cavaleri, the EMA’s head of vaccine strategy, told reporters, when asked about Merck’s drug.
(Reporting by Francesco Guarascio and Alistair Smout,; Editing by Louise Heavens)
